ArticleCell communication and signaling : CCS2026
TCOF1 affects Golgi secretory pathway contributing to the angiogenesis in renal cancer.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTCOF1 is a nucleolar protein involved in ribosome biogenesis, DNA damage response, and mitotic regulation. Germline TCOF1 mutations are associated with Treacher-Collins syndrome, a rare congenital disorder characterized by craniofacial abnormalities. Clear cell renal cell carcinoma (ccRCC), the most prevalent form of kidney cancer, exhibits pronounced nuclear and nucleolar pleomorphism, which correlates with tumour aggressiveness. The ccRCC grading system relies on microscopic evaluation of nuclear and nucleolar features. Here, we hypothesized that TCOF1 contributes to ccRCC tumorigenesis.
methodsThe study involved 200 tissue samples from ccRCC patients, two ccRCC-derived cell lines, and the publicly available cancer datasets. The used techniques included siRNA transfections, proliferation, viability, migration, and adhesion assays, proteomic and transcriptomic analyses, Western blot, real-time PCR, and angiogenesis evaluation using HUVEC cells.
resultsTCOF1 expression was elevated in ccRCC tumours and correlated with higher nucleolar grade and poorer patient survival. TCOF1 depletion altered the expression of multiple genes and proteins involved in the Golgi secretory pathway, including AVL9, GOLGA4, GOPC, RPS6KA5, SCAMP1, SEC24B, and STEAP3. These changes led to enhanced secretion of the anti-angiogenic thrombospondin 1 and suppression of angiogenesis. Furthermore, TCOF1 silencing downregulated several proteins implicated in craniofacial development, such as DCAF7 (aka WDR68), CHUK, APAF1, DICER1, and ETS1.
conclusionsTo our knowledge, this is the first study linking a nucleolar TCOF1 protein to the regulation of cellular secretion. Our findings suggest that elevated TCOF1 expression may disrupt the Golgi secretory pathway, inhibit thrombospondin 1 secretion, and promote angiogenesis in ccRCC. Our study also contributes to the understanding of the molecular consequences of TCOF1 dysfunction in Treacher-Collins syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.